JP Morgan Call 1020 REGN 16.08.20.../ DE000JB7W578 /
| 6/21/2024 11:21:50 AM | Chg.-0.030 | Bid11:22:10 AM | Ask11:22:10 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.510EUR | -5.56% | 0.520 Bid Size: 5,000 |
0.560 Ask Size: 5,000 |
Regeneron Pharmaceut... | 1,020.00 USD | 8/16/2024 | Call |
GlobeNewswire
6/18
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD ...
GlobeNewswire
6/16
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire
6/13
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
6/11
Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire
6/5
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
6/4
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire
6/3
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroG...
GlobeNewswire
5/31
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire
5/31
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
GlobeNewswire
5/31
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire
5/31
Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...
GlobeNewswire
5/28
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
5/23
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire
5/21
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
GlobeNewswire
5/20
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharma...
GlobeNewswire
5/20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
5/20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
5/20
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encou...
GlobeNewswire
5/17
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
